Study guide

14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease

Key Takeaways Explain This Topic AI

GERD is diagnosed clinically in patients with typical pyrosis and regurgitation; the presence of alarm features (dysphagia, odynophagia, unexplained weight loss, anemia, age >50) mandates immediate esophagogastroduodenoscopy (EGD) to rule out malignancy, strictures, or Barrett esophagus.

Stepwise GERD pharmacotherapy progresses from lifestyle interventions and antacids to H2-receptor antagonists and proton pump inhibitors (PPIs taken 30–60 minutes before the first meal); long-term PPI risks include hypomagnesemia, vitamin B12 deficiency, bone fractures, and Clostridioides difficile colitis.

Irritable bowel syndrome (IBS) exhibits a 2- to 3-fold female predominance and is diagnosed using Rome IV criteria: recurrent abdominal pain ≥ 1 day/week over the last 3 months associated with ≥ 2 criteria: related to defecation, change in stool frequency, or change in stool form.

IBS management integrates dietary interventions (soluble psyllium fiber, 3-phase low-FODMAP diet) with targeted pharmacotherapy: antispasmodics for postprandial cramping, secretagogues (lubiprostone, linaclotide) for IBS-C, and loperamide, rifaximin, or alosetron (under REMS) for IBS-D.

Female sex steroids heavily drive cholelithiasis: estrogen upregulates hepatic cholesterol secretion while progesterone impairs gallbladder motility; transabdominal ultrasound is first-line imaging, reliably distinguishing self-limiting biliary colic from acute cholecystitis (persistent RUQ pain >6 hours, fever, leukocytosis, positive Murphy sign).

Last updated: October 2026

Gastroesophageal Reflux Disease (GERD) in Women

Gastroesophageal reflux disease (GERD) is characterized by retrograde flow of gastroduodenal contents into the esophagus, producing bothersome symptoms or mucosal injury.

Pathophysiologic Mechanisms & Female Hormones

Reflux is primarily driven by transient lower esophageal sphincter relaxations (TLESRs) —abrupt vasovagal relaxations of the lower esophageal sphincter (LES) unassociated with swallowing. Contributing factors include low resting LES tone (<10 mmHg), sliding hiatal hernia, impaired esophageal clearance, and delayed gastric emptying. In women, sex hormones exert direct effects: progesterone relaxes gastrointestinal smooth muscle , lowering LES basal pressure during the luteal phase of menses and throughout gestation, where elevated progesterone combines with gravid uterine compression to cause pyrosis in up to 80% of pregnant women.

Clinical Presentation: Esophageal vs. Extraesophageal Symptoms

Classic Esophageal Symptoms: Pyrosis (substernal burning pain occurring 30 to 60 minutes postprandially and worsened by recumbency or bending forward) and acid regurgitation (sour fluid rising into the hypopharynx).

Extraesophageal Symptoms: Chronic dry cough, morning hoarseness, asthma exacerbation, globus sensation, dental enamel erosion, and non-cardiac chest pain (which mimics myocardial ischemia and mandates ruling out acute coronary syndrome first).

Diagnostic Approach & Endoscopic Alarm Indicators

In women presenting with typical pyrosis and regurgitation and no alarm features , clinical guidelines endorse an empiric 4- to 8-week trial of once-daily proton pump inhibitor (PPI) therapy as both diagnostic and therapeutic.

Indications for Upper Endoscopy (EGD) & Alarm Signs

Diagnostic upper endoscopy ( esophagogastroduodenoscopy [EGD] ) is mandatory when patients exhibit any of the following alarm features , fail twice-daily PPI therapy, or require screening for Barrett esophagus:

Clinical Alarm Feature Pathologic Risk / Underlying Differential

Dysphagia (difficulty swallowing solids or liquids) Peptic esophageal stricture, esophageal ring/web, eosinophilic esophagitis, or esophageal adenocarcinoma.

Odynophagia (painful swallowing) Severe erosive esophagitis, infectious ulceration (Candida, HSV, CMV), or pill esophagitis.

Unintentional Weight Loss Advanced gastrointestinal malignancy.

Gastrointestinal Bleeding / Anemia Hematemesis, melena, or occult blood loss causing iron deficiency anemia.

Persistent Protracted Vomiting Gastric outlet obstruction, severe gastroparesis, or mechanical small bowel obstruction.

New Symptom Onset at Age >50 Years Markedly elevated baseline risk of upper GI malignancies.

Barrett Esophagus Surveillance

Chronic reflux can induce Barrett esophagus , the metaplastic replacement of stratified squamous epithelium with specialized intestinal columnar epithelium containing goblet cells . Barrett esophagus is a premalignant precursor to esophageal adenocarcinoma . Patients with confirmed Barrett esophagus without dysplasia require surveillance EGD every 3 to 5 years.

  • Stepwise Management of GERD & Long-Term PPI Safety
  • 1. Lifestyle & Behavioral Interventions

Weight Loss: Reduces intragastric pressure, providing significant reflux relief in women with overweight or obesity.

Head of Bed Elevation: Elevate the head of the bed by 6 to 8 inches (15–20 cm) using bedframe risers or a firm foam wedge pillow. Gravity prevents nocturnal esophageal acid exposure.

Postprandial Positioning: Avoid lying down or assuming recumbency for at least 2 to 3 hours following meals .

Dietary Trigger Avoidance: Eliminate triggers that relax the LES or irritate mucosa: high-fat meals, caffeine, chocolate, peppermint, citrus fruits, tomato-based foods, alcohol, and carbonated beverages.

2. Pharmacotherapy: Antacids, H2RAs, and PPIs

Antacids & Alginates: (Calcium carbonate, magnesium hydroxide). Provide rapid neutralization of gastric acid lasting 30 to 60 minutes. Safe for episodic mild heartburn and first-line in pregnancy.

H2-Receptor Antagonists (H2RAs): (Famotidine 20–40 mg once or twice daily). Competitively inhibit H2 receptors on gastric parietal cells. Effective for mild-to-moderate symptoms or nocturnal breakthrough. Safe during pregnancy and lactation; chronic daily use induces tachyphylaxis within 2 to 6 weeks.

Proton Pump Inhibitors (PPIs): (Omeprazole 20–40 mg, Pantoprazole 40 mg daily). Irreversibly inhibit H+/K+ ATPase pumps in parietal cells. Patient Counseling: PPIs must be taken strictly 30 to 60 minutes before the first meal of the day , when the maximal number of proton pumps are recruited.

3. Long-Term PPI Safety Risks & Deprescribing

Chronic, uninterrupted PPI therapy carries recognized physiologic complications resulting from hypochlorhydria:

Micronutrient Malabsorption: Impaired acid-mediated ionization of vitamin B12 and non-heme iron , and reduced solubility of calcium carbonate (calcium citrate remains absorbed independent of acid).

Bone Fractures & Osteopenia: Increased risk of hip, wrist, and spine fractures in postmenopausal women.

Hypomagnesemia: Impaired intestinal magnesium transport; can produce tetany and arrhythmias; monitor serum magnesium periodically.

Enteric Infections: Doubled risk of Clostridioides difficile colitis and bacterial gastroenteritis.

Acute Interstitial Nephritis (AIN): Idiosyncratic immune reaction causing renal impairment.

Note

For uncomplicated GERD, prescribe an initial 8-week course of once-daily PPI. At 8 weeks, attempt to taper to the lowest effective dose or transition to on-demand H2RA therapy. Patients with severe erosive esophagitis (Los Angeles Grade C or D) or Barrett esophagus require lifelong continuous maintenance PPI.

Irritable Bowel Syndrome (IBS): Rome IV Diagnostic Framework

Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction characterized by recurrent abdominal pain and altered bowel habits without identifiable structural pathology. It demonstrates a 2- to 3-fold higher prevalence in females , with symptoms fluctuating across the menstrual cycle (worsening pain and looser stools during the late luteal and early menses phases due to progesterone drop and prostaglandin surge).

Rome IV Diagnostic Criteria

Diagnosis requires recurrent abdominal pain , on average, at least 1 day per week in the last 3 months , associated with two or more of the following:

Related to defecation (either improved or worsened by defecation).

Associated with a change in stool frequency (more or fewer bowel movements).

Associated with a change in stool form / appearance (stools becoming looser or harder, graded on the Bristol Stool Form Scale).

Criteria must be fulfilled for the preceding 3 months, with initial symptom onset occurring at least 6 months prior to clinical evaluation.

Subtype Classification (Bristol Stool Form Scale)

Subtyping guides targeted pharmacotherapy, assessed on days when bowel movements are abnormal:

IBS with Constipation (IBS-C): >25% hard or lumpy stools (Bristol Types 1–2) and <25% loose or watery stools (Bristol Types 6–7).

IBS with Diarrhea (IBS-D): >25% loose or watery stools (Bristol Types 6–7) and <25% hard or lumpy stools (Bristol Types 1–2).

IBS with Mixed Bowel Habits (IBS-M): >25% hard or lumpy stools AND >25% loose or watery stools.

IBS Unclassified (IBS-U): Meets pain criteria whose stool consistency abnormalities do not fit into other categories.

Diagnostic Workup & Exclusion of Organic Disease

In young female patients meeting Rome IV criteria without alarm features, invasive testing is unnecessary. The ACG recommends a limited diagnostic evaluation :

  • Complete Blood Count (CBC) to screen for anemia
  • C-reactive protein (CRP) or fecal calprotectin (FCP) to rule out Inflammatory Bowel Disease
  • Serologic celiac disease screening with serum IgA tissue transglutaminase (tTG-IgA)

Routine colonoscopy is NOT indicated in patients under age 45 unless alarm features are present (rectal bleeding, nocturnal diarrhea awakening the patient, unintended weight loss, fever, or family history of colorectal cancer or IBD).

  • Evidence-Based Management of IBS
  • Non-Pharmacologic Therapies

Soluble Fiber: Psyllium (ispaghula husk) 10 to 25 grams daily improves symptoms and stool transit. Insoluble fiber (coarse wheat bran) often worsens bloating and gas.

Low-FODMAP Diet: Restricts Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols. Implemented under registered dietitian guidance in three phases: Elimination (2–6 weeks) , Reintroduction , and Personalization .

Psychological Therapies: Gut-directed cognitive behavioral therapy (CBT) and hypnotherapy modulate the bidirectional brain-gut axis.

Pharmacotherapy for IBS Subtypes

Antispasmodics: (Dicyclomine 10–20 mg, Hyoscyamine 0.125–0.25 mg taken 30–60 minutes before meals). Anticholinergics that blunt postprandial cramping; adverse effects include dry mouth and blurred vision.

Targeted Agents for IBS-C:

Osmotic Laxatives: Polyethylene glycol (PEG 3350) softens stool but does not significantly reduce abdominal pain.

Intestinal Secretagogues: Lubiprostone (8 mcg BID in adult women), a type-2 chloride channel (ClC-2) activator; Linaclotide (72–290 mcg daily) and Plecanatide , guanylate cyclase-C (GC-C) agonists that increase luminal fluid secretion, accelerate transit, and dampen nociceptive pain signaling.

Targeted Agents for IBS-D:

Peripheral Opioid Agonists: Loperamide (2–4 mg titrated) slows transit but does not relieve visceral pain.

Non-Absorbable Antibiotic: Rifaximin (550 mg TID for 14 days). Modulates the colonic microbiome, suppresses gas production, and relieves bloating and diarrhea.

5-HT3 Receptor Antagonists: Alosetron (0.5–1.0 mg daily or BID). Serotonin antagonist approved strictly for women with severe chronic IBS-D refractory to conventional therapies . Due to risks of ischemic colitis and serious constipation complications, alosetron is distributed under an FDA-mandated REMS program.

Neuromodulators: Low-dose Tricyclic Antidepressants (TCAs) (Amitriptyline 10–25 mg at bedtime) blunt central pain processing and prolong transit time in IBS-D.

Gallbladder Disease: Cholelithiasis, Biliary Colic & Acute Cholecystitis

Gallstone disease demonstrates a 2- to 3-fold higher incidence in women than men during reproductive years.

Hormonal Pathogenesis: Estrogen, Progesterone & "The 4 Fs"

The clinical mnemonic "Female, Fat, Fertile, Forty" encapsulates core pathophysiologic mechanisms driven by sex hormones:

Estrogen Drives Cholesterol Supersaturation: Estrogen upregulates hepatic HMG-CoA reductase activity, enhancing cholesterol synthesis and hypersecreting cholesterol into bile. Bile becomes supersaturated, precipitating cholesterol monohydrate crystal nucleation and stone formation.

Progesterone Drives Gallbladder Hypomotility & Stasis: Progesterone impairs gallbladder smooth muscle contraction by diminishing cholecystokinin (CCK) receptor sensitivity. Gallbladder hypomotility leads to bile stasis, allowing cholesterol crystals to aggregate into macro-calculi. Pregnancy, high-dose oral contraceptives, and multiparity accelerate lithogenesis.

Metabolic Factors: Obesity and rapid weight loss (e.g., post-bariatric surgery) dramatically elevate biliary cholesterol saturation.

Clinical Spectrum: Biliary Colic vs. Acute Cholecystitis

Clinical Parameter Symptomatic Cholelithiasis (Biliary Colic) Acute Cholecystitis

Underlying Pathology Transient obstruction of the cystic duct by a gallstone during gallbladder contraction. Persistent, sustained cystic duct impaction producing mucosal ischemia, inflammation, and secondary bacterial infection.

Pain Characteristics Severe, episodic RUQ or epigastric pain radiating to the right infrascapular area or shoulder. Persistent, unremitting, severe RUQ pain radiating to the shoulder/back; progressive peritoneal irritation.

Duration of Pain 1 to 5 hours (typically resolves within 4–6 hours as stone dislodges). >6 hours (typically lasts 12 to 24+ hours; does not resolve spontaneously).

Systemic Signs Afebrile ; normal vital signs. Nausea may accompany pain. Fever , chills, tachycardia, anorexia, nausea, and vomiting.

Physical Examination Mild RUQ tenderness; no peritoneal signs ; negative Murphy sign between episodes. Marked focal RUQ tenderness, guarding, positive Murphy sign .

Laboratory Findings Completely normal (normal WBC, bilirubin, AST/ALT/ALP, lipase). Leukocytosis with left shift; transaminases and bilirubin may be mildly elevated.

Definitive Treatment Outpatient elective laparoscopic cholecystectomy ; dietary low-fat counseling while awaiting surgery. Hospital admission, NPO, IV fluid resuscitation, IV broad-spectrum antibiotics, and urgent laparoscopic cholecystectomy (within 24–72 hours).

The Murphy Sign

A hallmark bedside clinical physical finding in acute cholecystitis. The examiner deeply palpates the patient's right subcostal margin while the patient inspires deeply. As the inflamed gallbladder contacts the examiner's fingers, the patient experiences sudden sharp pain and exhibits an abrupt arrest of inspiratory effort ( inspiratory arrest = positive Murphy sign ).

Diagnostic Imaging Modalities

Transabdominal Ultrasonography: The initial imaging modality of choice (sensitivity and specificity >95% for cholelithiasis). Sonographic findings diagnostic of acute cholecystitis include:

Gallstones or biliary sludge with posterior acoustic shadowing .

Gallbladder wall thickening (>3 mm).

Pericholecystic fluid halo (extraluminal fluid accumulation).

Sonographic Murphy Sign: Maximal focal tenderness elicited directly over the sonographically visualized gallbladder using the ultrasound transducer.

Cholescintigraphy (HIDA Scan): Technetium-99m labeled hepatobiliary iminodiacetic acid is injected IV and excreted into bile. If the gallbladder is not visualized within 1 to 4 hours while the radiotracer freely enters the common bile duct and duodenum, cystic duct obstruction is confirmed, establishing definitive diagnosis of acute cholecystitis (indicated when ultrasound is equivocal).

Important

If a patient presents with RUQ pain accompanied by jaundice (elevated total and direct bilirubin) and marked transaminase/alkaline phosphatase elevation, evaluate urgently for choledocholithiasis (stone in common bile duct) or acute ascending cholangitis ( Charcot triad: fever, jaundice, RUQ pain; or Reynolds pentad: + hypotension and altered mental status, an emergency requiring urgent endoscopic retrograde cholangiopancreatography [ERCP]).